VARSHA V GANDHI to Proto-Oncogene Proteins c-met
This is a "connection" page, showing publications VARSHA V GANDHI has written about Proto-Oncogene Proteins c-met.
Connection Strength
1.300
-
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.
Score: 0.397
-
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
Score: 0.364
-
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007 Oct 15; 67(20):9913-20.
Score: 0.238
-
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
Score: 0.114
-
MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 2009 Jul 18; 280(1):1-14.
Score: 0.065
-
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 2009 Mar; 63(4):587-97.
Score: 0.062
-
RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol. 2008 Mar; 140(6):682-391.
Score: 0.061